Caribou Biosciences Filter Stocks by Fundamentals

Key Indicators . Net Income . Stocks . USA . 
Stock . Caribou Biosciences
CRBU Stock  USD 1.87  -0.01  -0.53%   
Caribou Biosciences' reported Net Income and the formula behind it are documented below with the most recent data. This metric is computed using a widely recognized formula in financial analysis.
=

null

The latest Net Income figure for Caribou Biosciences tracks the most recent filing period. Filing frequency determines whether quarterly or annual data appears.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Institutional Holders

Institutional Holdings for Caribou Biosciences encompasses the stake held by mutual funds, pension funds, and insurers. These holders often own significant blocks of Caribou Biosciences' stock and can influence corporate governance decisions. Declining institutional holdings for Caribou Biosciences' can indicate that professional investors are reducing exposure.
Shares
Geode Capital Management, Llc2025-12-31
976.8 K
Partner Fund Management Lp2025-12-31
957.8 K
Marshall Wace Asset Management Ltd2025-12-31
881.1 K
Jacobs Levy Equity Management, Inc.2025-12-31
824.3 K
Millennium Management Llc
767 K
Fmr Inc2025-12-31
726 K
Maverick Capital Ltd2025-12-31
652.5 K
Cambridge Invest Research Advisors, Inc.2025-12-31
581.8 K
Charles Schwab Investment Management Inc2025-12-31
555.6 K
Pfizer Inc2025-12-31
4.7 M
Vanguard Group Inc2025-12-31
4.3 M

Important Fundamentals

Return On Equity TTM-0.79
Return On Asset TTM-0.34
Operating Margin TTM-7.22
Current Valuation75.56 M
Shares Outstanding98.68 M
Shares Owned By Insiders8.96 %
Shares Owned By Institutions36.50 %
Number Of Shares Shorted6.77 M
Price To Book TTM1.54 X
Price To Sales TTM17.24 X
Revenue TTM11.16 M
Gross Profit TTM-96.36 M
EBITDA TTM-132.55 M
Net Income TTM-148.12 M
Cash And Equivalents TTM339.92 M
Cash Per Share TTM5.59 X
Total Debt TTM27.23 M
Debt To Equity TTM0.08 %
Current Ratio TTM12.23 X
Book Value Per Share TTM1.28 X
Cash Flow From Operations TTM-110.99 M
Short Ratio TTM5.85 X
Earnings Per Share-1.59 X
Price To Earnings To Growth0.50 X
Target Price11.71
Number Of Employees97
Trailing Beta2.28
Market Capitalization TTM192.43 M
Total Asset TTM175.37 M
Retained Earnings TTM-596.51 M
Working Capital TTM119.82 M
Net Asset175.37 M

Financial Metrics, Fundamentals & Methodology

Caribou Biosciences's core fundamentals cover profitability, capital efficiency, and funding structure. Return on equity helps show how effectively management is turning capital into earnings. For the latest reporting period, Caribou Biosciences reports revenue of 11.16 million, EPS loss of 1.59, negative operating margin of 7.22%.

Caribou Biosciences figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Income statement, balance sheet, and cash-flow values follow GAAP or IFRS conventions as reported.

Editorial review and methodology oversight provided by: Vlad Skutelnik, Macroaxis Contributor


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.